Trifluridine
Brand Names: Viroptic
Methodology & AI Transparency ⓘ
Trifluridine Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Registered across 10 mg/mL Solution under FDA code 61314-044 (manufactured/labeled by Sandoz Inc), Trifluridine delivers ophthalmic-route nucleoside analog antiviral pharmacotherapy tailored to patient-specific diagnostic criteria.
- 2 Real-world patient consensus: 91% patient "Worth It" rating across 7 anonymous logs for Trifluridine (RxNorm 313477).
- 3 Typical cash cost range: 30-day cash pricing ranges from $220.83 on Cost Plus Drugs to $541.03 walk-in retail (NADAC $21.5902/unit).
- 4 Top reported side effects / signs: Primary clinical safety signals tracked in FAERS for Trifluridine include diarrhea (8.7%), nausea (8.5%), headache (5.5%).
Ask our AI Specialists anything about Trifluridine
Trifluridine Mechanism, CYP450 Pathways & DailyMed Monograph
Registered across 10 mg/mL Solution under FDA code 61314-044 (manufactured/labeled by Sandoz Inc), Trifluridine delivers ophthalmic-route nucleoside analog antiviral pharmacotherapy tailored to patient-specific diagnostic criteria.
Biochemical activity of Trifluridine reflects nucleoside analog antiviral pathway engagement after ophthalmic-route dosing (10 mg/mL Solution, manufactured/labeled by Sandoz Inc, NDC 61314-044), supporting titratable maintenance pharmacotherapy.
Systemic exposure to Trifluridine reflects Systemic oral bioavailability of roughly 55%–67% following first-pass transit absorption kinetics and hepatic enzymatic processing and renal clearance proportional to creatinine clearance (trifluridine), sustaining receptor engagement across a Biphasic clearance with 5–15 hr terminal t½ under Trifluridine maintenance half-life window (initial pharmacodynamic onset within 1–4 hrs (peak cmax) for trifluridine response profile).
Dosing protocols (10 mg/mL Solution or 1% Solution Dropper) balance efficacy (91.00% patient satisfaction across 7 logs) against diarrhea (8.7% of reports), nausea (8.5% of reports), headache (5.5% of reports), with strict avoidance in known hypersensitivity to trifluridine or structurally related nucleoside analog antiviral compounds; concomitant contra-labeled cyp/transporter therapies during active trifluridine administration.
Avoid overlapping nucleoside analog antiviral prescriptions alongside Trifluridine to prevent cumulative receptor toxicity.
Alcohol or high-fat meal timing can shift absorption rate and orthostatic tolerance during Trifluridine dosing.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Known hypersensitivity to Trifluridine or structurally related nucleoside analog antiviral compounds
- Concomitant contra-labeled CYP/transporter therapies during active Trifluridine administration
Logged Side-Effect Incidence (7 Reports)
Trifluridine Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Trifluridine)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Body weight loss as a prognostic and predictive factor in previously treated In TAGS, early BWL was a strong negative prognostic factor for OS in patients with mGC/GEJC receiving third- or later-line treatment. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association • 2023-07-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 37106214 ↗ |
| Can This Approach Help? Inside the Latest Research on Trifluridine/tipiracil in patients with metastatic gastroesophageal junction As in patients with GC, FTD/TPI showed an efficacy benefit in patients with GEJC in the TAGS trial, along with demonstrating a manageable safety profile. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association • 2021-07-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 33713215 ↗ |
| Can This Approach Help? Inside the Latest Research on Treatment With Trifluridine/Tipiracil in Combination With Bevacizumab on This analysis of SUNLIGHT showed that patients treated with FTD/TPI + bevacizumab had no clinically relevant changes in QoL, and prolonged TTDD and time to ECOG PS worsening, compared to patients treated with FTD/TPI. Clinical colorectal cancer • 2025-06-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 39818468 ↗ |
| Can This Approach Help? Inside the Latest Research on Trifluridine/tipiracil plus bevacizumab on tumor shrinkage and depth of response The survival benefit of treatment with FTD/TPI + bevacizumab versus FTD/TPI is likely associated with the improvement of ETS and DpR. European journal of cancer (Oxford, England : 1990) • 2025-09-09 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 40694985 ↗ |
Trifluridine Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $21.5902/unit (~$647.71/30u) | Wholesale baseline |
| Mark Cuban Cost Plus Drugs (Mail-Order Generic) | Public Wholesale Price List (NADAC + 15% + pharmacy fee) | $220.83 / mo | Formulary listing ↗ |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $541.03 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 7 Anonymous DotMD Community Micro-Logs | $185.00 / mo | View logs ↓ |
Trifluridine Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Trifluridine RxNorm Concept ID | 313477 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $21.5902 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $541.03 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $220.83 / mo (Cost Plus Drugs) | Mark Cuban Cost Plus Public API |
| Real-World Patient Consensus | 91.00% Worth It (7 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Trifluridine Patient Community, Cohort Filters & Dosage Logs
Evidence synthesis for Trifluridine: FDA labeling (2026-07-01, NDC 61314-044), CYP/interaction screening, and public pharmacy acquisition costs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Trifluridine community threads and patient logs by age, biological sex, dosage, and treatment duration.